Nehal Masood, MD
Hematology & Oncology · Tacoma, WANPI 1407291230
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $205 and has fallen 60.4% since, to $81 in 2025. That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.
Across 19 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$116
- Pfizer$102
- E.r. Squibb & Sons, L.L.C.$101
- Sanofi$81
- Bristol Myers Squibb$63
- Pharmacyclics LLC, An Abbvie Company$45
- plus $37 from 2 others
Across 113 payments — averaging $8552.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$386K
- Novartis$126K
- Merck$76K
- Astrazeneca UK Limited$70K
- Eli Lilly$55K
- Genentech, Inc.$51K
- plus $202K from 11 others
What the payments were for
- Food & beverage$50893%
- Education$387%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 1 | $116 |
| Pfizer | 2 | $102 |
| E.r. Squibb & Sons, L.L.C. | 7 | $101 |
| Sanofi | 1 | $81 |
| Bristol Myers Squibb | 4 | $63 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $45 |
| Gilead | 1 | $25 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$547 in reported general payments places this provider in the 40th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 14 | $348,042 |
| ErleadaApalutamide | 22 | $330,970 |
| RevlimidLenalidomide | 16 | $327,779 |
| TukysaTucatinib | 11 | $265,014 |
| CabometyxCabozantinib S-Malate | 11 | $264,547 |
| InlytaAxitinib | 12 | $245,904 |
| NerlynxNeratinib Maleate | 12 | $203,697 |
| TagrissoOsimertinib Mesylate | 11 | $186,228 |
| ImbruvicaIbrutinib | 11 | $180,166 |
| EliquisApixaban | 236 | $164,424 |
| PromactaEltrombopag Olamine | 11 | $144,985 |
| LonsurfTrifluridine/Tipiracil Hcl | 13 | $134,129 |
| Abiraterone Acetate | 55 | $71,341 |
| CreonLipase/Protease/Amylase | 12 | $28,658 |
| XareltoRivaroxaban | 21 | $18,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Eliquis | $102 | $410,328248 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $101 | $348,04214 claims |
| Bristol Myers SquibbRevlimid | $63 | $327,77916 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $45 | $180,16611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Tacoma
- Jorge ChavesTacoma$27K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.